Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: A follow-up of the Eastern Cooperative Oncology Group E3A98 trial

Morie A. Gertz, Rafat Abonour, Leonard T. Heffner, Philip R. Greipp, Hajime Uno, S. V. Rajkumar

Research output: Contribution to journalArticle

36 Scopus citations


Waldenström macroglobulinaemia is a low-grade, lymphoplasmacytic lymphoma that is responsive to rituximab. We report the role of a minor response in predicting overall outcomes. We extended follow-up of a previously described cohort (n = 69) treated with 4 weekly doses of rituximab and observed durable responses (median time to progression, 30 months; 5-year survival rate, 66%). Patients achieving a minor response [25-50% immunoglobulin M (IgM) reduction] appeared to do as well as those achieving an objective response (>50% IgM reduction), which suggests that more aggressive or intensive therapy for minor responders is not required. Future studies of Waldenström macroglobulinaemia should report minor responses because they are associated with clinically meaningful benefits. This trial was registered at as #NCT00005609.

Original languageEnglish (US)
Pages (from-to)677-680
Number of pages4
JournalBritish journal of haematology
Issue number5
StatePublished - Dec 1 2009



  • Lymphoplasmacytic lymphoma
  • Monoclonal IgM protein
  • Rituximab
  • Waldenström macroglobulinaemia

ASJC Scopus subject areas

  • Hematology

Cite this